LYMPHOMA, SMALL LYMPHOCYTIC
Clinical trials for LYMPHOMA, SMALL LYMPHOCYTIC explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, SMALL LYMPHOCYTIC trials appear
Sign up with your email to follow new studies for LYMPHOMA, SMALL LYMPHOCYTIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a treatment called JCAR017, which uses a patient's own immune cells that are modified in a lab to better find and attack cancer cells. It is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
New hope for blood cancer patients: drug combo aims to control relapsed CLL
Disease control Recruiting nowThis study tests whether a new drug, nemtabrutinib, combined with venetoclax works better than the standard venetoclax plus rituximab for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. Abou…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New study monitors Long-Term safety of pirtobrutinib in blood cancer patients
Disease control Recruiting nowThis study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibitor. It is open to 150 participants who completed a previous related study. Part…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
CAR-T patients monitored for decades in new safety study
Knowledge-focused Recruiting nowThis study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC